Tumor promotion in rat liver

Area of Science:

• Hepatocarcinogenesis research
• Toxicology and pharmacology

Background:

• A bioassay for chemical carcinogens and tumor promoters was developed using rat liver foci of gamma-glutamyltranspeptidase (GGTase)-positive hepatocytes as an endpoint.
• Phenobarbital is a known inducer of liver enzymes and has been investigated for its tumor-promoting potential.

Purpose of the Study:

• To evaluate the tumor-promoting activity of phenobarbital in a rat liver model.
• To assess the stability and progression of preneoplastic lesions under continuous and interrupted phenobarbital promotion.

Main Methods:

• Rats were initiated with diethylnitrosamine (DENA) and promoted with phenobarbital in drinking water.
• Partial hepatectomy was used to induce liver regeneration before DENA administration and phenobarbital promotion.
• GGTase-positive foci and liver tumors were quantified over time in groups with continuous or interrupted phenobarbital treatment.

Main Results:

• Phenobarbital promotion significantly increased the incidence and size of GGTase-positive foci compared to controls.
• Continuous phenobarbital promotion led to a higher incidence of liver tumors by 81 weeks compared to interrupted promotion.
• Interrupted phenobarbital treatment did not cause regression of foci, which continued to increase in number and size.

Conclusions:

• Phenobarbital acts as a potent tumor promoter in rat liver, accelerating the development of GGTase-positive foci and liver tumors.
• The study demonstrates the utility of GGTase-positive foci as a reliable endpoint for evaluating tumor promoters.
• Continuous promotion is more effective in driving tumor progression than interrupted promotion.